News · 26 weeks97-59%
2025-12-142026-06-07
Mix4690d
- Insider25(54%)
- SEC Filings8(17%)
- Other7(15%)
- Analyst3(7%)
- Earnings3(7%)
Latest news
25 items- INSIDERChief Operating Officer Adsett Roger sold $242,380 worth of shares (2,370 units at $102.27), decreasing direct ownership by 2% to 98,603 units (SEC Form 4) (tax liability)4 - INSMED Inc (0001104506) (Issuer)
- INSIDERChief Financial Officer Bonstein Sara sold $245,857 worth of shares (2,404 units at $102.27), decreasing direct ownership by 3% to 69,082 units (SEC Form 4) (tax withholding)4 - INSMED Inc (0001104506) (Issuer)
- INSIDERChief Legal Officer Smith Michael Alexander sold $220,801 worth of shares (2,159 units at $102.27), decreasing direct ownership by 5% to 39,454 units (SEC Form 4) (tax liability)4 - INSMED Inc (0001104506) (Issuer)
- INSIDERChief Medical Officer Flammer Martina M.D. sold $455,248 worth of shares (4,424 units at $102.90) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 60,486 units (SEC Form 4) to satisfy withholding obligation4 - INSMED Inc (0001104506) (Issuer)
- INSIDERChair and CEO Lewis William sold $777,763 worth of shares (7,605 units at $102.27), decreasing direct ownership by 3% to 265,432 units (SEC Form 4) (for tax liability)4 - INSMED Inc (0001104506) (Issuer)
- PRInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)BRIDGEWATER, N.J., June 4, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 103 new employees. The awards were granted under the Insmed Incorporated 2025 Inducement Plan, which is intended to meet the requirements of a plan providing for inducement grants under Nasdaq Listing Rule 5635(c)(4). The awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.In connection with the commence
- PRInsmed to Present at the 2026 Goldman Sachs Annual Global Healthcare ConferenceBRIDGEWATER, N.J., May 27, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the 2026 Goldman Sachs Annual Global Healthcare Conference in Miami on Tuesday, June 9, 2026, at 10:00 a.m. ET.This event will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. This webcast will be archived for a period of 30 days following the conclusion of this live event.About InsmedInsmed Incorporated is a people-first global b
- INSIDERChief Legal Officer Smith Michael Alexander sold $666,982 worth of shares (6,149 units at $108.47) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 41,613 units (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- INSIDERChair and CEO Lewis William exercised 10,699 shares at a strike of $24.94 and sold $2,718,224 worth of shares (25,564 units at $106.33) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 273,037 units (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- SECSEC Form S-3ASR filed by Insmed IncorporatedS-3ASR - INSMED Inc (0001104506) (Filer)
- INSIDERChief Financial Officer Bonstein Sara sold $961,041 worth of shares (8,272 units at $116.18), decreasing direct ownership by 10% to 71,486 units (SEC Form 4) (withholding obligation)4 - INSMED Inc (0001104506) (Issuer)
- INSIDERDirector Schafer Carol was granted 3,305 shares, increasing direct ownership by 5% to 66,622 units (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- INSIDERChief Legal Officer Smith Michael Alexander sold $477,384 worth of shares (4,109 units at $116.18), decreasing direct ownership by 8% to 47,762 units (SEC Form 4) to satisfy tax liability4 - INSMED Inc (0001104506) (Issuer)
- INSIDERChief Medical Officer Flammer Martina M.D. sold $2,128,892 worth of shares (18,333 units at $116.12) as part of a pre-agreed trading plan, decreasing direct ownership by 22% to 64,910 units (SEC Form 4) (tax liability)4 - INSMED Inc (0001104506) (Issuer)
- INSIDERChief Operating Officer Adsett Roger sold $678,143 worth of shares (5,837 units at $116.18), decreasing direct ownership by 5% to 100,973 units (SEC Form 4) (for withholding tax)4 - INSMED Inc (0001104506) (Issuer)
- INSIDERDirector Anderson Elizabeth M was granted 3,305 shares, increasing direct ownership by 6% to 62,034 units (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- INSIDERSEC Form 4 filed by Insmed Incorporated4 - INSMED Inc (0001104506) (Issuer)
- INSIDERDirector Brennan David R was granted 3,305 shares, increasing direct ownership by 5% to 64,238 units (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- INSIDERDirector Lee Leo was granted 3,305 shares, increasing direct ownership by 6% to 57,971 units (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- INSIDERDirector Desjardins Clarissa was granted 3,305 shares, increasing direct ownership by 5% to 70,312 units (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- INSIDERChair and CEO Lewis William sold $1,543,219 worth of shares (13,283 units at $116.18), decreasing direct ownership by 4% to 287,902 units (SEC Form 4) (withholding obligation)4 - INSMED Inc (0001104506) (Issuer)
- SECInsmed Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - INSMED Inc (0001104506) (Filer)
- INSIDERChief Medical Officer Flammer Martina M.D. exercised 12,949 shares at a strike of $17.07 and sold $1,300,121 worth of shares (12,949 units at $100.40) as part of a pre-agreed trading plan (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- SECInsmed Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - INSMED Inc (0001104506) (Filer)
- SECSEC Form 10-Q filed by Insmed Incorporated10-Q - INSMED Inc (0001104506) (Filer)
INSM FAQ
6 questionsWhat does Insmed Incorporated do?
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the...Where does INSM stock trade?
Insmed Incorporated (INSM) is listed on NASDAQ.What sector and industry is INSM in?
Insmed Incorporated operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about INSM?
Insmed Incorporated has had 8 recent analyst actions on file. The most recent action was from Raymond James: Outperform on 2026-04-10.What companies are similar to INSM?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare INSM side-by-side with any of them on Quantisnow.How can I track INSM on Quantisnow?
Quantisnow aggregates Insmed Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INSM to receive live email and push alerts on every new disclosure.